Prognostic systems proposed for patients with myelodysplastic syndromes.
| . | Stated Major Components of Prognostic System . | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prognostic system . | Pt. PS . | Pt. Age . | Hb. or Transf. . | WBC/ANC . | Plt. . | LDH . | Blood blasts . | Marrow blasts . | Marrow morphology* . | Cyto-genetics . | FAB classification . | WHO classification . | First Author . | Journal/Year Published . |
| * Includes abnormal localization of immature precursors (ALIP), marrow fibrosis, marrow cellularity, myeloid:erythroid ratio, or cellular dysplasia. | ||||||||||||||
| Comments: The list of prognostic systems excludes systems proposed specifically for chronic myelomonocytic leukemia (CMML), such as the modified Bournemouth score and the MD Anderson CMML proposal, since CMML is classified separately from MDS by the WHO. | ||||||||||||||
| Note that some columns are not entirely independent of others; for instance, blood counts and marrow and blood blast proportion contribute to the WHO classification. | ||||||||||||||
| IPSS indicates International Prognostic Scoring System; WPSS, WHO-based Prognostic Scoring System; MDACC, MD Anderson Cancer Center; Pt., patient; PS, performance status; Hb., hemoglobin; WBC, white blood count; ANC, absolute neutrophil count; Plt, platelet count; LDH, lactate dehydrogenase; Trans., transfusion requirement; Cytogen, cytogenetic results (either complexity, specific abnormalities, or proportion of abnormal metaphases); FAB, French-American-British classification; class., classification. | ||||||||||||||
| Bournemouth | X | X | X | X | Mufti | Br J Haem 1985 | ||||||||
| Dutch | X | X | X | X | Kerkhofs | Br J Haem 1987 | ||||||||
| Sanz (Spanish) | X | X | X | X | X | Sanz | Blood 1989 | |||||||
| Pavia | X | X | X | Cassano | Haematologica 1990 | |||||||||
| Rennes “3-D” | X | X | X | Goasquen | Leuk Res 1990 | |||||||||
| Düsseldorf | X | X | X | X | Aul | Leukemia 1992 | ||||||||
| Japanese | X | X | X | X | X | Toyama | Leukemia 1993 | |||||||
| Hannover Histopathology | X | X | X | Maschek | Eur J Haem 1994 | |||||||||
| Lille | X | X | X | X | X | X | Morel | Leukemia 1996 | ||||||
| IPSS | X | X | X | X | X | X | Greenberg | Blood 1997 | ||||||
| WPSS | X | X | X | Malcovati | J Clin Onc 2007 | |||||||||
| MDACC (Lower-risk) | X | X | X | X | X | Garcia-Manero | Leukemia 2008 | |||||||
| MDACC (General) | X | X | X | X | X | X | X | Kantarjian | Cancer 2008 | |||||
| Modified WPSS | X | X | X | X | Della Porta | Haematologica 2009 | ||||||||
| . | Stated Major Components of Prognostic System . | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prognostic system . | Pt. PS . | Pt. Age . | Hb. or Transf. . | WBC/ANC . | Plt. . | LDH . | Blood blasts . | Marrow blasts . | Marrow morphology* . | Cyto-genetics . | FAB classification . | WHO classification . | First Author . | Journal/Year Published . |
| * Includes abnormal localization of immature precursors (ALIP), marrow fibrosis, marrow cellularity, myeloid:erythroid ratio, or cellular dysplasia. | ||||||||||||||
| Comments: The list of prognostic systems excludes systems proposed specifically for chronic myelomonocytic leukemia (CMML), such as the modified Bournemouth score and the MD Anderson CMML proposal, since CMML is classified separately from MDS by the WHO. | ||||||||||||||
| Note that some columns are not entirely independent of others; for instance, blood counts and marrow and blood blast proportion contribute to the WHO classification. | ||||||||||||||
| IPSS indicates International Prognostic Scoring System; WPSS, WHO-based Prognostic Scoring System; MDACC, MD Anderson Cancer Center; Pt., patient; PS, performance status; Hb., hemoglobin; WBC, white blood count; ANC, absolute neutrophil count; Plt, platelet count; LDH, lactate dehydrogenase; Trans., transfusion requirement; Cytogen, cytogenetic results (either complexity, specific abnormalities, or proportion of abnormal metaphases); FAB, French-American-British classification; class., classification. | ||||||||||||||
| Bournemouth | X | X | X | X | Mufti | Br J Haem 1985 | ||||||||
| Dutch | X | X | X | X | Kerkhofs | Br J Haem 1987 | ||||||||
| Sanz (Spanish) | X | X | X | X | X | Sanz | Blood 1989 | |||||||
| Pavia | X | X | X | Cassano | Haematologica 1990 | |||||||||
| Rennes “3-D” | X | X | X | Goasquen | Leuk Res 1990 | |||||||||
| Düsseldorf | X | X | X | X | Aul | Leukemia 1992 | ||||||||
| Japanese | X | X | X | X | X | Toyama | Leukemia 1993 | |||||||
| Hannover Histopathology | X | X | X | Maschek | Eur J Haem 1994 | |||||||||
| Lille | X | X | X | X | X | X | Morel | Leukemia 1996 | ||||||
| IPSS | X | X | X | X | X | X | Greenberg | Blood 1997 | ||||||
| WPSS | X | X | X | Malcovati | J Clin Onc 2007 | |||||||||
| MDACC (Lower-risk) | X | X | X | X | X | Garcia-Manero | Leukemia 2008 | |||||||
| MDACC (General) | X | X | X | X | X | X | X | Kantarjian | Cancer 2008 | |||||
| Modified WPSS | X | X | X | X | Della Porta | Haematologica 2009 | ||||||||